Ironwood Pharmaceuticals/$IRWD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
- Ticker
- $IRWD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 100
- Headquarters
- Boston, United States
- Website
- ironwoodpharma.com
IRWD Metrics
BasicAdvanced
$806M
5.37
$0.91
0.24
-
Price and volume
Market cap
$806M
Beta
0.24
52-week high
$5.78
52-week low
$2.85
Average daily volume
2.2M
Financial strength
Current ratio
6.507
Quick ratio
6.308
Long term debt to equity
-3.425
Total debt to equity
-3.459
Interest coverage (TTM)
8.81%
Profitability
EBITDA (TTM)
253.423
Gross margin (TTM)
76.37%
Net profit margin (TTM)
37.38%
Operating margin (TTM)
62.88%
Effective tax rate (TTM)
34.07%
Revenue per employee (TTM)
$4,000,000
Management effectiveness
Return on assets (TTM)
45.80%
Return on equity (TTM)
-82.81%
Valuation
Price to earnings (TTM)
5.369
Price to revenue (TTM)
1.993
Price to book
-8.3
Price to tangible book (TTM)
-8.18
Price to free cash flow (TTM)
3.884
Free cash flow yield (TTM)
25.75%
Free cash flow per share (TTM)
1.254
Growth
Revenue change (TTM)
18.09%
Earnings per share change (TTM)
412.03%
3-year revenue growth (CAGR)
-2.54%
10-year revenue growth (CAGR)
5.26%
3-year earnings per share growth (CAGR)
-47.18%
10-year earnings per share growth (CAGR)
4.73%
What the Analysts think about IRWD
Analyst ratings (Buy, Hold, Sell) for Ironwood Pharmaceuticals stock.
Analyst projections of the future price of Ironwood Pharmaceuticals stock.
Bulls say / Bears say
LINZESS demand rose 4.9% in the third quarter, and Ironwood raised its 2026 sales guidance to $1.20–$1.25 billion. The stronger outlook supports the case that the brand’s turnaround is continuing. (Ironwood Pharmaceuticals)
The FDA expanded LINZESS use for functional constipation to children aged two and older. This gives the established brand access to a broader patient group. (Ironwood Pharmaceuticals)
Ironwood reported $60 million of third-quarter GAAP net income and record adjusted EBITDA of $98 million, while reducing its revolving debt by $60 million. Stronger earnings and debt repayment could improve financial flexibility. (Ironwood Pharmaceuticals)
Revenue remains highly dependent on LINZESS: U.S. collaboration revenue was $129.9 million of Ironwood’s $133.0 million total revenue in the third quarter. A setback to this one brand could therefore have a large effect on the business. (Ironwood Pharmaceuticals)
Alkem has sought approval to sell generic LINZESS capsules before the listed patents expire, prompting a patent-infringement suit. An adverse outcome could expose the brand to earlier generic competition and pressure sales. (DocketNexus)
Apraglutide still needs a confirmatory Phase 3 trial after FDA discussions, with Ironwood targeting a regulatory filing in 2029 only if the trial succeeds. That leaves a long wait and material clinical and approval risk before the pipeline can add revenue. (Ironwood Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
IRWD Financial Performance
Revenues and expenses
IRWD Earnings Performance
Company profitability
Upcoming events
No upcoming events
IRWD News
AllArticlesVideos
What Ironwood Pharmaceuticals (IRWD) Said on Its Q3 Earnings Call
MarketBeat1 week ago
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
Business Wire4 weeks ago
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
Business Wire2 months ago
Funds containing IRWD
Fund name | Fund size | $IRWD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.05% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.03% |
Xtrackers S&P 500 Swap£XSPX | $9.1B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.